GBR 13069

GBR 13069 is a drug that acts as a potent and selective dopamine reuptake inhibitor. It is primarily used in scientific research, particularly in studies involving the dopaminergic system.

Chemistry[edit | edit source]

GBR 13069 is a derivative of vanoxerine, a potent dopamine reuptake inhibitor. It is structurally similar to GBR 12909 and GBR 12935, other potent dopamine reuptake inhibitors. The chemical structure of GBR 13069 includes a diphenylmethoxy group, which is thought to contribute to its high potency and selectivity for the dopamine transporter.

Pharmacology[edit | edit source]

GBR 13069 acts by binding to the dopamine transporter (DAT), thereby inhibiting the reuptake of dopamine into presynaptic neurons. This results in an increase in the extracellular concentration of dopamine, leading to increased dopaminergic neurotransmission.

The drug has a high affinity for the dopamine transporter, but a much lower affinity for the norepinephrine transporter (NET) and the serotonin transporter (SERT). This selectivity makes GBR 13069 a useful tool in the study of the dopaminergic system.

Uses in Research[edit | edit source]

GBR 13069 is primarily used in scientific research. It has been used in studies investigating the role of the dopaminergic system in various conditions, including Parkinson's disease, schizophrenia, and drug addiction. It has also been used to study the effects of dopamine reuptake inhibition on behavior and cognition.